US 12,109,410 B2
Bioelectric stimulator
Howard J. Leonhardt, Corona Del Mar, CA (US); and Jorge Genovese, Buenos Aires (AR)
Assigned to LEONHARDT VENTURES LLC, Corona Del Mar, CA (US)
Filed by LEONHARDT VENTURES LLC, Corona Del Mar, CA (US)
Filed on Mar. 29, 2021, as Appl. No. 17/216,423.
Application 17/216,423 is a continuation of application No. 15/812,760, filed on Nov. 14, 2017, granted, now 10,960,206.
Application 15/812,760 is a continuation in part of application No. 15/460,129, filed on Mar. 15, 2017, granted, now 10,646,644, issued on May 11, 2020.
Claims priority of provisional application 62/454,521, filed on Feb. 3, 2017.
Claims priority of provisional application 62/385,124, filed on Sep. 8, 2016.
Claims priority of provisional application 62/375,271, filed on Aug. 15, 2016.
Claims priority of provisional application 62/364,472, filed on Jul. 20, 2016.
Claims priority of provisional application 62/363,012, filed on Jul. 15, 2016.
Claims priority of provisional application 62/352,930, filed on Jun. 21, 2016.
Claims priority of provisional application 62/308,702, filed on Mar. 15, 2016.
Prior Publication US 2021/0236817 A1, Aug. 5, 2021
Int. Cl. A61N 1/32 (2006.01); A61B 5/243 (2021.01); A61M 5/142 (2006.01); A61M 39/00 (2006.01); A61M 39/02 (2006.01); A61N 1/36 (2006.01); A61N 1/362 (2006.01); A61N 1/372 (2006.01); A61N 1/375 (2006.01)
CPC A61N 1/326 (2013.01) [A61M 39/0208 (2013.01); A61N 1/37205 (2013.01); A61N 1/375 (2013.01); A61B 5/243 (2021.01); A61M 5/14276 (2013.01); A61M 2039/0036 (2013.01); A61M 2202/07 (2013.01); A61M 2205/05 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61N 1/36002 (2017.08); A61N 1/36007 (2013.01); A61N 1/36071 (2013.01); A61N 1/36114 (2013.01); A61N 1/3629 (2017.08)] 15 Claims
OG exemplary drawing
 
1. A method of using a bioelectric stimulator to stimulate target tissue of a subject to control stem cell homing, proliferation, or differentiation and/or upregulate expression of at least one protein by the target tissue, wherein the protein is selected from the group consisting of activin, epidermal growth factor (EGF), follistatin, hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), platelet-derived growth factor (PDGF), receptor activator of nuclear factor kappa-B ligand (RANKL), stromal cell-derived factor 1 (SDF1), tropoelastin, vascular endothelial growth factor (VEGF) and any combination thereof, the method comprising:
delivering at least one bioelectric signal to the target tissue so as to control stem cell homing, proliferation, or differentiation and/or to upregulate expression of at least one protein in the target tissue, wherein the bioelectric signal(s) comprise(s) at least one bioelectric signal(s) selected from the group consisting of
(a) 2 Hz, square biphasic wave, pulse width 1,000 μs so as to upregulate expression of RANKL by the target tissue;
(b) within 15%, 30 Hz, square biphasic wave, pulse width 100 μs so as to upregulate expression of SDF1 to the target tissue and stimulate stem cell homing to the target tissue;
(c) within 15%, 100 Hz, square biphasic wave, pulse width 100 μs so as to upregulate expression of PDGF and stimulate stem cell homing to the target tissue;
(d) 20 Hz, square wave, pulse width 200 to 700 μs so as to stimulate stem cell proliferation;
(e) 10 Hz, square biphasic wave, pulse width 200 μs so as to upregulate expression of PDGF by the target tissue and stem cell homing to the target tissue;
(f) within 15%, 150 Hz, monophasic square wave, pulse width 100 μs so as to upregulate expression of activin by the target tissue;
(g) within 15%, 500 Hz, square biphasic wave, pulse-width 180 μs so as to upregulate expression of EGF by the target tissue;
(h) within 15%, 22 Hz, square monophasic wave, pulse width 50% duty cycle so as to upregulate expression of IGF-1 by the target tissue;
(i) 70 Hz, square wave, pulse width 10%-50% duty cycle,
(j) 200 picoamps with a pulse having an amplitude of 5 V and a width of 0.5 milliseconds so as to stimulate stem cell proliferation;
(k) 50 Hz, square wave so as to upregulate expression of follistatin, tropoelastin, VEGF and HGF by the target tissue, and
(l) any combination(s) thereof.